GLP-1 Agonist Prescribing

You'll be able to select, initiate, and titrate GLP-1 and GIP receptor agonist therapy for patients with obesity while anticipating and managing common side effects.

Practice this in the app More Medical weight loss tracks

What this track covers

This track covers GLP-1 and dual GIP/GLP-1 receptor agonists used in obesity treatment, including their mechanisms of action, product differences, and practical prescribing considerations. It focuses on the clinical judgment needed to individualize therapy across patient presentations and treatment phases.

What you will practice

Screening patients for appropriate candidacy and contraindications
Comparing mechanisms across available GLP-1 and GIP/GLP-1 agents
Structuring titration schedules around tolerability
Recognizing and managing gastrointestinal side effects
Adjusting plans for plateaus or inadequate response

Simulator scenario

A simulated patient with obesity and prediabetes presenting for an initial visit to discuss starting a GLP-1 agonist, requiring history-taking, contraindication screening, and a shared decision-making conversation.

Board question topics

Mechanism of action and receptor targets
Contraindications and precautions
Titration and dose adjustment principles
Recognizing and managing adverse effects

Ask the tutor

What are the labeled contraindications for GLP-1 receptor agonists?Opens the tutor · answers cite their sources How do GIP/GLP-1 dual agonists differ mechanistically from GLP-1-only agents?Opens the tutor · answers cite their sources What does the label say about managing persistent GI side effects during titration?Opens the tutor · answers cite their sources

The tutor only answers from licensed sources (FDA prescribing information, public guidelines and our own material) and says when it has none. Educational use only, never patient-specific advice.

Free during the beta. Sign in with your email, no password.

Start free